RCMI Coordinating Center (RCMI CC) Header Logo

Connection

José F. Rodríguez-Orengo to Antiviral Agents

Back to Details
This is a "connection" page, showing publications José F. Rodríguez-Orengo has written about Antiviral Agents.
José F. Rodríguez-Orengo
Connection Strength
0.725
Antiviral Agents
  1. Rodr?guez-Torres M, Burguera J, Hallman D, Rodr?guez-Orengo J, Echeandia M. ?Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. Ann Hepatol. 2012 Jul-Aug; 11(4):450-63.
    View in: PubMed
    Score: 0.391
  2. Rodr?guez-Torres M, Rodr?guez-Orengo JF, R?os-Bedoya CF, Fern?ndez-Carbia A, Marxuach-Cu?tara AM, L?pez-Torres A, Jim?nez-Rivera J. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol. 2007 Apr; 46(4):613-9.
    View in: PubMed
    Score: 0.268
  3. Rodr?guez-Torres M, Rodr?guez-Orengo JF, R?os-Bedoya CF, Fern?ndez-Carbia A, Gonz?lez-Lassalle E, Salgado-Mercado R, Marxuach-Cu?tara AM. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007 Jan; 38(1):32-8.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support